Table 7 Cost-effectiveness (95% CI) of ART compared to no-ART under different scenarios
From: Cost-effectiveness of anti-retroviral therapy at a district hospital in southern Ethiopia
Strategy | Life time Cost $ | Life time incremental cost | Life years gain | Incremental life years gain | Cost effectiveness ($) | Incremental Cost Effectiveness ratio (ICER $) | % change from base case ICER |
|---|---|---|---|---|---|---|---|
a) | |||||||
no-ART | 264(82–1046) | 2.4(1.99–2.82) | 110(36–433) | ||||
ART | 2713(1038–5883) | 2448(653–5665) | 10.4(9.45–11.23) | 8(6.96–8.91) | 262(101–564) | 307(83–708) | -2.2 |
b) | |||||||
no-ART | 265(85–1148) | 2.3(1.95–2.73) | 114(38–504) | ||||
ART | 3022(1486–6054) | 2757(1080–5885) | 11.4(10.46–12.41) | 9.1(8.03–10.18) | 264(129–525) | 303(121–634) | -3.5 |
c) | |||||||
no-ART | 265(85–1148) | 2.3(1.95–2.73) | 114(38–504) | ||||
ART* | 2537(1281–4859) | 2273(851–4647) | 9.4(8.67–10.05) | 7.1(6.24–7.83) | 271(137–519) | 322(120–662) | 2.6 |
ART** | 2576(1313–4937) | 2311(844–4740) | 9.4(8.67–10.05) | 7.1(6.24–7.83) | 275(141–525_ | 328(123–668) | 4.5 |
ART*** | 2672(1413–5069) | 2407(1020–4841) | 9.4(8.67–10.05) | 7.1(6.24–7.83) | 285(151–539) | 341(145–684) | 8.6 |
d) | |||||||
no-ART | 265(85–1148) | 2.3(1.95–2.73) | 114(38–504) | ||||
ART | 1150(621–2099) | 886(-100–1924) | 4.3(3.99–4.67) | 2.0(1.49–2.53) | 266(145–482) | 441(-49–1009) | 40.5 |